Prof. Dr. Nezih Meydan

Domaines d’intérêt médical indiqués par le médecin lui-même sur sa page du site de l’établissement. Source : medicana.com.tr.

Expérience

• 1991-1993Artvin (Mecburi Hizmet)medicana.com.tr
• 1993-1998Dokuz Eylül Üniversitesi Tıp Fakültesi, İç Hastalıkları ABDmedicana.com.tr
• 1998-2001Dokuz Eylül Üniversitesi Tıp Fakakültesi Erişkin Hematoloji-Onkoloji Bilim Dalı, Uzman Doktormedicana.com.tr
• 2001-2006Adnan Menderes Üniv.Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji Bilim Dalı, Yardımcı Doçentmedicana.com.tr
• 2006-2011Adnan Menderes Üniv.Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji Bilim Dalı, Doçentmedicana.com.tr
• 2011-2021Adnan Menderes Üniv.Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji Bilim Dalı, Profesörmedicana.com.tr

Formation

• 1991Anadolu Üniversitesimedicana.com.tr
• 2001Dokuz Eylül Üniversitesi, Tıbbi Onkolojimedicana.com.tr

• SpécialitéOncologie médicalemedicana.com.trD’après la source
• Nom du service dans la sourceMedikal Onkolojimedicana.com.trD’après la source
• ÉtablissementMedicana International Istanbul - Beylikdüzümedicana.com.trD’après la source
• Publications94 publicationspage de profil sur medicana.com.trD’après la source
• Dernière synchronisation7 novembre 2026 03:18https://www.medicana.com.tr/hekim-detay/12603/nezih-meydanmedicana.com.tr

1. 1.Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I, Meydan N. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. J Cancer Res Ther. 2020 Jul- Sep;16(4):737-744. doi: 10.4103/jcrt.JCRT_1404_16. PMID: 32930112.

   Source : page de profil sur medicana.com.tr

2. 2.Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer. 2020 Oct;148:48-54. doi:10.1016/ j.lungcan. 2020.07.022. Epub 2020 Jul 27. PMID: 32799090.

   Source : page de profil sur medicana.com.tr

3. 3.Benekli M, Gumus M, Ozkan M, Dane F, Elkiran ET, Cicin I, Sevinc A, Aliustaoglu M, Isikdogan A, Meydan N, Oksuzoglu B, Ozyilkan O, Artac M, Ozdemir F, Kilickap S. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. J Oncol Pharm Pract. 2020 Oct 13:1078155220963535. doi: 10.1177/1078155220963535. Epub ahead of print. PMID: 33050804.

   Source : page de profil sur medicana.com.tr

4. 4.Yersal Ö, Kaplan MA, Işikdoğan A, Özdemir N, Aliustaoğlu M, Barutca S, Erdoğdu Hİ, Meydan N. Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era. Mol Clin Oncol. 2019 Jan;10(1):180-184. doi: 10.3892/mco.2018.1771. Epub 2018 Nov 19. PMID: 30655995; PMCID: PMC6313943.

   Source : page de profil sur medicana.com.tr

5. 5.Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I, Meydan N. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. J Cancer Res Ther. 2018 Dec;14(Supplement):S1201-S1208. doi: 10.4103/jcrt.JCRT_1404_16. PMID: 30539871.

   Source : page de profil sur medicana.com.tr

6. 6.Yersal Ö, Eryilmaz U, Akdam H, Meydan N, Barutca S. Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens. Cardiol Res Pract. 2018 May 2;2018:5352914. doi: 10.1155/2018/5352914. PMID: 29854434; PMCID: PMC5954934.

   Source : page de profil sur medicana.com.tr

7. 7.Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, Menekse S, Kocar M, Sen CA, Ordu C, Goksel G, Meydan N, Barutca S; Turkish Descriptive Oncological Researches Group. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2018 Mar;12(3):922-929. doi: 10.1111/crj.12605. Epub 2017 Jan 6. PMID: 28026133.

   Source : page de profil sur medicana.com.tr

8. 8.Aykan NF, Yalçın S, Turhal NS, Özdoğan M, Demir G, Özkan M, Yaren A, Camcı C, Akbulut H, Artaç M, Meydan N, Uygun K, Işıkdoğan A, Ünsal D, Özyılkan Ö, Arıcan A, Seyrek E, Tekin SB, Manavoğlu O, Özet A, Elkıran T, Dişçi R. Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial). Turk J Gastroenterol. 2015 Mar;26(2):145-53. doi: 10.5152/tjg.2015.5685. PMID: 25835113.

   Source : page de profil sur medicana.com.tr

9. 9.Tanriverdi O, Avci N, Oktay E, Kalemci S, Pilanci KN, Cokmert S, Menekse S, Kocar M, Sen CA, Akman T, Ordu C, Goksel G, Meydan N, Barutca S. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group. Asian Pac J Cancer Prev. 2015;16(14):5971-6. doi: 10.7314/apjcp.2015.16.14.5971. PMID: 26320482.

   Source : page de profil sur medicana.com.tr

10. 10.Tanriverdi O, Meydan N, Barutca S. Reconsideration of clinical and histopathological prognostic factors in breast cancer patients: a single center experience. Asian Pac J Cancer Prev. 2014;15(2):807-12. doi: 10.7314/apjcp.2014.15.2.807. PMID: 24568500.

    Source : page de profil sur medicana.com.tr